Biodistribution and localization of iodine-131 labeled metuximab in patients with hepatocellular carcinoma

PURPOSE: Radioimmunotherapy may improve the outcome of hepatocellular carcinoma(HCC) patients by delivering targeted radiation to liver lesion tissue while relatively sparing nontarget tissues. This study was designed to observe the biodistribution, localization and imaging characteristics of 131I -labeled Metuximab in 24 patients with HCC to determine the diagnositic and therapeutic potential of this antibody. METHODS: 24 HCC patients were randomly divided into three groups to receive 18.5, 27.75 and 37 MBq/kg of 131I-labeled Metuximab per kilogram of body weight, respectively. 99mTc-sodium phytate was administered intravenously and the single photon emission computed tomography ?SPECT) scanning was performed. After 48 h, Iodine-131 labeled Metuximab was injected by hepatic artery intubation, and SPECT scan performed at 7d. The percentage of absorbed 131I (?ID) and the time-dependent 131I tumor:non-tumor tissue (T/NT) ratios were calculated at 12, 48, 96 and 192h after injection. RESULTS: The positive Imaging result of MAb scanning in 24 patients showed that the iodine 131 conjugated to Metuximab was apparently accumulated more in hepatoma. Biodistribution studies of 131I-Metuximab in trial I demonstrated that the comparable %ID uptake in tumor (with a T/NT ratio at 12, 48, 96 and 192h) to that in such normal organs, as thyroid, heart, lung, spleen and intestines were all more than 1. The optimal imaging time for the highest T/NT ratio in liver was at 192h. CONCLUSION: 131I-labeled Metuximab could delivere relatively selective radiation to tumor tissues and may have potential efficacy in relieving hepatocellular carcinoma.

[1]  R. Sharma,et al.  Influence of administration route on tumor uptake and biodistribution of etoposide loaded solid lipid nanoparticles in Dalton's lymphoma tumor bearing mice. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[2]  G. Rustin,et al.  Vascular disrupting agents: a new class of drug in cancer therapy. , 2005, Clinical oncology (Royal College of Radiologists (Great Britain)).

[3]  A. Canutescu,et al.  Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth , 2005, Molecular Cancer Therapeutics.

[4]  S. Hirohashi,et al.  Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma , 2005, Cancer.

[5]  F. Appelbaum,et al.  Biodistribution of yttrium-90-labeled anti-CD45 antibody in a nonhuman primate model. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  M. Yu,et al.  HAb18G/CD147-mediated calcium mobilization and hepatoma metastasis require both C-terminal and N-terminal domains , 2004, Cellular and Molecular Life Sciences CMLS.

[7]  S. Knox,et al.  Radiobiology of radioimmunotherapy with 90Y ibritumomab tiuxetan (Zevalin). , 2003, Seminars in oncology.

[8]  D. Goldenberg,et al.  Tumor-specific dose scheduling of bimodal radioimmunotherapy and chemotherapy. , 2003, Anticancer research.

[9]  J. Li,et al.  Pharmacokinetics of radioimmunotherapeutic agent of direct labeling mAb 188Re-HAb18. , 2002, World journal of gastroenterology.

[10]  H. Chan,et al.  The Involvement of HAb18G/CD147 in Regulation of Store-operated Calcium Entry and Metastasis of Human Hepatoma Cells* , 2001, The Journal of Biological Chemistry.

[11]  M. Bukrinsky,et al.  CD147 facilitates HIV-1 infection by interacting with virus-associated cyclophilin A , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[12]  S. Mather,et al.  High efficiency iodination of monoclonal antibodies for radiotherapy. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  B. Toole.  Emmprin (CD147), a cell surface regulator of matrix metalloproteinase production and function. , 2003, Current topics in developmental biology.